The European inhalable drug market is anticipated to grow at a CAGR of 3.3% over the forecast period (2020-2026). The key factors that drive the growth of the market include the support by the key players functioning in the market, rising geriatric population, sedentary lifestyles, along with the change in eating habits of the people. The major countries of Europe considered in the report include the UK, France, Germany, Italy, Spain, and the Rest of Europe.
To Request a Sample of our Report on Europe Inhalable Drugs Market: https://www.omrglobal.com/request-sample/europe-inhalable-drugs-market
The UK is considered a promising market for the European inhalable drug industry. According to Diabetes UK, in 2019, there were almost 3.7 million people who were diagnosed with diabetes in the country, representing 6% of the UK population. This represents 1 in every 16 people with suffer from diabetes. By 2025, it is estimated that five million people are likely to suffer from diabetes in the UK, according to Diabetes UK. This creates demand for inhalable insulin, especially among aged people, and hence creates scope for market growth.
Besides, the key player’s contributions are also further driving the European market over the forecast period. F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Boehringer Ingelheim GmbH, and AstraZeneca Plc are some of the players operating in the market in the region. These players adopt several growth strategies such as product launches, innovations, mergers, and acquisitions in order to thrive in the competitive market. For instance, in February 2017, Boehringer Ingelheim Pharmaceuticals announced that the FDA approved SPIRIVA RESPIMAT, an inhalable spray, for the long-term, once-daily maintenance treatment of asthma in people age 6 and older.
Market Coverage
· Market number available for – 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Application and By Route of Administration
· Regions Covered- Europe
· Competitive Landscape- F. Hoffmann-La Roche Ltd., Novartis International AG, AstraZeneca Plc, Boehringer Ingelheim GmbH, and GlaxoSmithKline Plc
(Get 15% Discount on Buying this Report)
A full Report of Europe Inhalable Drugs Market is Available at: https://www.omrglobal.com/industry-reports/europe-inhalable-drugs-market
Europe Inhalable Drugs Market – Segmentation
By Application
· Respiratory Diseases
· Non- Respiratory Diseases
By Route of Administration
· Nasal
· Mouth
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
